⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Official Title: An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis

Study ID: NCT01439867

Study Description

Brief Summary: The primary objective was to characterize corrected serum calcium levels on treatment with cinacalcet in pediatric patients with secondary hyperparathyroidism (HPT).

Detailed Description: This is a multicenter, 26-week, single-arm, open-label, safety study. Participants were to remain on study for 26 weeks or until time of kidney transplantation, whichever came first. The study and enrollment was placed on partial clinical hold in February 2013 which resulted in changes to the protocol. The study was restarted in April 2014 following these changes. Participants who completed the 26-week study or were on study when the study was closed in June 2016 were eligible to participate in an open-label extension study (Study 20140159; NCT02341417).

Eligibility

Minimum Age: 28 Days

Eligible Ages: CHILD

Sex: ALL

Healthy Volunteers: No

Locations

Research Site, Birmingham, Alabama, United States

Research Site, Little Rock, Arkansas, United States

Research Site, Los Angeles, California, United States

Research Site, Iowa City, Iowa, United States

Research Site, Louisville, Kentucky, United States

Research Site, Baltimore, Maryland, United States

Research Site, Ann Arbor, Michigan, United States

Research Site, Kansas City, Missouri, United States

Research Site, Saint Louis, Missouri, United States

Research Site, Bronx, New York, United States

Research Site, Greenville, North Carolina, United States

Research Site, Cincinnati, Ohio, United States

Research Site, Oklahoma City, Oklahoma, United States

Research Site, Philadelphia, Pennsylvania, United States

Research Site, Dallas, Texas, United States

Research Site, Houston, Texas, United States

Research Site, San Antonio, Texas, United States

Research Site, Bruxelles, , Belgium

Research Site, Gent, , Belgium

Research Site, Leuven, , Belgium

Research Site, Praha 5, , Czechia

Research Site, Bron cedex, , France

Research Site, Lille, , France

Research Site, Paris, , France

Research Site, Paris, , France

Research Site, Paris, , France

Research Site, Heidelberg, , Germany

Research Site, Budapest, , Hungary

Research Site, Debrecen, , Hungary

Research Site, Szeged, , Hungary

Research Site, Genova, , Italy

Research Site, Roma, , Italy

Research Site, Torino, , Italy

Research Site, Chihuahua, , Mexico

Research Site, Amsterdam, , Netherlands

Research Site, Grafton, Auckland, , New Zealand

Research Site, Gdansk, , Poland

Research Site, Krakow, , Poland

Research Site, Warszawa, , Poland

Research Site, Moscow, , Russian Federation

Research Site, Saint Petersburg, , Russian Federation

Research Site, Kosice, , Slovakia

Contact Details

Name: MD

Affiliation: Amgen

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: